American Heart Association Scientific Sessions

Dr Roland Chen Discusses the Primary Endpoints of the GUARD-AF Trial for Atrial Fibrillation

January 31, 2020

The GUARD-AF trial will allow us to look at both the benefits and the risks of screening for atrial fibrillation and the reduction of stroke, said Roland Chen, MD, MS, vice president and head of clinical development for innovative medicines at Bristol-Myers Squibb.

Dr Jay Edelberg Explains Preventive Efficacy and Potential FDA Approval of Mavacamten

January 26, 2020

We are really excited about the progress we have seen in the EXPLORER-HCM trial, and after the results are published in the first half of 2020, we will quickly begin conversations to seek FDA approval of mavacamten, said Jay Edelberg, MD, PhD, senior vice president of Clinical Development at MyoKardia.

Dr Jay Edelberg Discusses PIONEER-OLE and Design of EXPLORER-HCM in Patients With Obstructive HCM

January 16, 2020

Results of the PIONEER-OLE study has shown promising results of mavacamten for patients with obstructive HCM that will be further evaluated in our pivotal phase 3 EXPLORER-HCM trial, said Jay Edelberg, MD, PhD, senior vice president of Clinical Development at MyoKardia.

Dr Javed Butler Discusses Why People With Diabetes Are at Greater Risk of Heart Failure

January 11, 2020

There are multiple ways in which people with diabetes can develop heart failure, which is why heightened awareness through the initiative Diabetes Can Break Your Heart is warranted, said Javed Butler, MD, MPH, MBA, professor of physiology and chairman for the Department of Medicine at the University of Mississippi.

Dr Darryl Sleep: Identifying and Treating Elevated LDL-C in Patients Can Mitigate Heart Attack Risk

December 06, 2019

Identifying elevated LDL-C levels in patients and treating them with evolocumab can potentially mitigate and reduce the rate of ischemic events, said Darryl Sleep, MD, senior vice president, global medical and chief medical officer at Amgen.

Dr Roland Chen Outlines the GUARD-AF Trial as a Preventive Mechanism in Reducing Risk of Stroke

December 06, 2019

The GUARD-AF trial promotes heightened knowledge of stroke risk among patients with atrial fibrillation by analyzing, evaluating, and distributing important data back to practitioners, which can possibly reduce the incidence of stroke, said Roland Chen, MD, MS, vice president and head of clinical development for innovative medicines at Bristol-Myers Squibb.

Dr Brian Ghoshhajra Details the Significance of the PDS-2 System in Affecting Progression of HoFH

December 05, 2019

The HDL PDS-2 system showed in a relatively short time its ability to affect the progression of HoFH, with a reduction in the burden of plaque overall highlighting its exciting potential, said Brian Ghoshhajra, MD, MBA, diagnostic radiologist and service chief of cardiovascular imaging in the Department of Radiology at Massachusetts General Hospital.

Dr Douglas Losordo Discusses the Evolution and Importance of CD34+ Treatment in Patients With CMD

December 05, 2019

We've had the opportunity to evaluate the CD34+ cell in the past 20 years, and finally we have a tool that represents a potential breakthrough for patients with CMD, said Douglas Losordo, MD, FACC, FAHA, chief medical officer at Caladrius Biosciences.

Dr Brandon Fornwalt Discusses the Preventive Efficacy of AI in Monitoring for Atrial Fibrillation

November 30, 2019

Artificial intelligence has the potential to change the way physicians have monitored for conditions such as atrial fibrillation in the past 5 decades, said Brandon Fornwalt, MD, PhD, director of the Cardiac Imaging Technology Laboratory at Geisinger.